RNR catalyses the reduction of ribonucleoside diphosphates to deoxyribonucleoside diphosphates, and is a long-standing anti-cancer target that can be inhibited by several chemotherapeutic agents, such as hydroxyurea and gemcitabine. Here, NR2E3 is linked to cancer.